Clinical trials: Phase I
Malignant Melanoma
A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma
This study aims to evaluate safety and effect of combining an oncolytic adenovirus (delolimogene mupadenorepvec; LOAd703) with atezolizumab in patients with melanoma.
- Trial name
- NCT04123470
- Testing
- delolimogene mupadenorepvec, atezolizumab
- Where
- 3 sites in United States, Sweden
- Volunteers
- 24 people
- Sponsor
- Lokon Pharma AB
Plasmodium Falciparum Malaria
Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children
To assess the safety and reactogenicity of the FMP-1/AS02A malaria vaccine in malaria-exposed children living in western Kenya and aged 12-47 months
- Trial name
- NCT00317473
- Testing
- FMP1/AS02A Malaria vaccine, Imovax Rabies vaccine
- Where
- Kenya
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Diabetes
A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus
This is a first-in-human evaluation of CT-388 in a double blind, placebo controlled, randomized, SAD/MAD/MD, safety, tolerance, PK, and PD study when administered as a SC injection in otherwise healthy overweight and obese adult…
- Trial name
- NCT04838405
- Testing
- CT-388
- Where
- 2 sites in Australia, Mexico
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Carmot Therapeutics, Inc.
Melanoma (Skin)
Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00538005
- Testing
- bevacizumab, oxaliplatin, sorafenib tosylate
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- San Diego Pacific Oncology & Hematology Associates
Zika Virus
Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)
This study will include 4 cohorts of 14 ZIKV and DENV-naïve female and male subjects, 18 - 40 years of age (total: up to 56 subjects).
- Trial name
- NCT05123222
- Testing
- ZIKV-SJRP/2016-184 Strain, Experimental: ZIKV-Nicaragua/2016 Strain
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
This clinical trial studies peripheral blood hemapoietic stem cell mobilization with the combination of bortezomib and G-CSF (filgrastim) in multiple myeloma and non-Hodgkin lymphoma patients.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT02037256
- Testing
- bortezomib, filgrastim, autologous hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Small Cell Lung Cancer
Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer
The subjects are being asked to take part in the Phase I or Phase II portion of a research study of a new investigational drug, LBH589, in combination with chemotherapeutic agents, carboplatin with etoposide.
- Trial name
- NCT00958022
- Testing
- LBH589 and carboplatin with etoposide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Ahmad Tarhini
Unresectable Metastatic Colorectal Cancer
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
The purpose of the alloSHRINK study is to assess the safety, cell kinetics and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered after standard chemotherapy
- Trial name
- alloSHRINK (NCT03692429)
- Testing
- CYAD-101, FOLFOX, FOLFIRI
- Where
- 4 sites in United States, Belgium
- Volunteers
- 49 people
- Sponsor
- Celyad Oncology SA
Metastatic Cancer, Soft Tissue Sarcoma
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.
- Conditions
- Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma
- Trial name
- NCT04725331
- Testing
- BT-001, Pembrolizumab [KEYTRUDA®]
- Where
- 5 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Transgene
Idiopathic Pulmonary Fibrosis
Phase I/IIa Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Main purpose -To explore the safety and tolerance of human umbilical cord mesenchymal stem cells in the treatment of idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT05468502
- Testing
- Human umbilical cord mesenchymal stem cell injection
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Shanghai Life Science & Technology
Platinum-resistant Ovarian Cancer, Endometrial Cancer
A Study of DeTIL-0255 in Adults With Advanced Malignancies
This is a first-in-human Phase 1 multicenter, open-label oncology study designed to evaluate the safety and efficacy of NX-DeTIL-0255-201 in patients with advanced malignancies.
- Conditions
- Platinum-resistant Ovarian Cancer, Endometrial Cancer, Cervical Cancer
- Trial name
- NCT05107739
- Testing
- Drug Product De-TIL-0255
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Nurix Therapeutics, Inc.
Infectious Disease, COVID-19
Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273
Phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, and immunogenicity of RVM-V001 administered as a single intramuscular injection in healthy adults.
- Trial name
- NCT05420077
- Testing
- RVM-V001 10 µg, RVM-V001 30 µg, RVM-V001 60 µg
- Where
- 2 sites in Australia
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- RVAC Medicines (US), Inc.
Lymphoma, Thromboembolism
Heparin or Enoxaparin in Patients With Cancer
RATIONALE: Heparin or enoxaparin may be effective in preventing the formation of blood clots in patients with cancer who are undergoing surgery to remove the tumor.
- Conditions
- Lymphoma, Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00004875
- Testing
- enoxaparin, heparin
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Northwestern University
Herpes Zoster
A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
The study will evaluate the safety, tolerability, and immunogenicity (your immune system's reaction) of the study vaccine called Herpes Zoster IN001 mRNA Vaccine (IN001) in healthy participants who are between 50 and 69 years of…
- Trial name
- NCT06375512
- Testing
- HZ Vaccine (IN001), Shingrix
- Where
- 3 sites in United States, Australia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Shenzhen Shenxin Biotechnology Co., Ltd
Central Retinal Vein Occlusion
Phase I RVC With Ocriplasmin for CRVO
In central retinal vein occlusion (CRVO) a blood clot blocks the venous outflow of the entire retinal circulation. This leads to retinal and vitreous hemorrhages, retinal edema and neovascularization.
- Trial name
- RVC_CRVO (NCT02747030)
- Testing
- Ocriplasmin intravenously
- Where
- Belgium
- Volunteers
- 4 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
ALS
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
This study is a placebo-controlled Phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide (ASO) AMX0114 in adult participants with amyotrophic lateral sclerosis…
- Trial name
- LUMINA (NCT06665165)
- Testing
- AMX0114
- Where
- 14 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
This research study is evaluating a drug called cabozantinib as a possible treatment for acute myeloid leukemia (AML). This research study is a Phase I clinical trial.
- Trial name
- NCT01961765
- Testing
- cabozantinib
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer, Locally Advanced Breast Cancer
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
This randomized, placebo-controlled trial aims to assess the feasibility, acceptability, and preliminary efficacy of memantine and the University of Carolina (UNC)'s Get Real \& Heel cancer exercise program (MEM+EX) in addressing…
- Conditions
- Breast Cancer, Locally Advanced Breast Cancer, Cognitive Impairment, Cognitive Decline
- Trial name
- NCT06727773
- Testing
- Memantine, Exercise Intervention, Exercise Control
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Overweight or Obesity
A Study to Evaluate MWN109 Tablets in Healthy Adult Participants
This is a Phase 1, randomized, double-blind, placebo-controlled, single-and-multiple ascending dose study in which the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of orally administered…
- Trial name
- NCT06938269
- Testing
- MWN109 tablet
- Where
- 2 sites in Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Brain Tumor, Cancer
000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
Protocol # 000860 Background: Diffuse gliomas are tumors that affect the brain and spinal cord. Gliomas that develop in people with certain gene mutations (IDH1 or IDH2) are especially aggressive. Better treatments are needed.
- Trial name
- NCT05588141
- Testing
- Zotiraciclib
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.